Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beyond BRIC: 'Pharmerging' Markets Loom If Pharma Is To Expand -IMS Study

Executive Summary

Big Pharma needs to target emerging markets more aggressively - but not just the usual suspects. Brazil, Russia, India and China (BRIC) remain highly important, but in a March 16 report, IMS Health predicts that 17 countries, in total, will contribute 48 percent of annual market growth in 2013, up from 37 percent they contributed last year

You may also be interested in...

Pharmerging Markets, Led By China, Expected To Keep Sales Growth "Strong" Through 2014, IMS Says

Growth in "pharmerging" markets is so strong it is likely to nearly offset lost sales from genericization of some of pharma's biggest products in the next two years, IMS Health said April 20

Pharmerging Markets Expected To Keep Sales Growth "Strong" Through 2014, IMS Says

IMS forecasts a 5 percent to 8 percent growth of global pharmaceutical sales annually through 2014.

Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers

A new multi-pharma company collaboration is intended to dramatically speed development of new combination regimens for tuberculosis, but efforts to accelerate development may be hindered by the lack of biomarkers for TB

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts